PacBio Raises IPO Target to $230M, Enacts 1-for-2 Reverse Stock Split, Prices Shares | GenomeWeb

This article, originally published Oct. 1, has been updated with information from an additional amendment of Pacific Biosciences' S-1 form.

By Bernadette Toner

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.